AN2 Therapeutics (ANTX) Other Non-Current Liabilities (2025 - 2026)
AN2 Therapeutics (ANTX) reported Other Non-Current Liabilities of $170000.0 for Q1 2026, little changed quarter-over-quarter from $170000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 2 years of Other Non-Current Liabilities data on file, last reported at $170000.0 in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $170000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $170000.0 (changed N/A YoY), and the FY2025 annual result was $170000.0, changed N/A from the prior year.
- Other Non-Current Liabilities held at $170000.0 in Q1 2026 per ANTX's latest filing, from $170000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $170000.0 in Q4 2025 and troughed at $170000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 170,000.00 |
| Dec 31, 2025 | 170,000.00 |